This article provides details on the GSGR6369814 bond issued by The Goldman Sachs Group, Inc., including its price, chart data, and key terms. The bond is a Series N Medium Term Note with a 5.7% coupon rate, maturing on April 16, 2046, and has an outstanding face value of $1,000.00. The article also describes Goldman Sachs' business segments and offers access to advanced bond data for registered users.

Taseko Mines (TSX:TKO) has seen significant share price appreciation, with a 34% increase in the past month and 2.6x return over one year, bringing its multi-year total returns to about 3.7x. Analysts currently peg the fair value at CA$12.61, suggesting an 18% undervaluation from its last close of CA$10.53, based on expectations of improved free cash flow and potential deleveraging from operational gains. However, its current P/S ratio of 5.7x is above its fair ratio of 3.5x, indicating potential overpricing relative to sales, and risks such as permitting setbacks are noted.

Teleflex Incorporated (NYSE: TFX) has nominated Michael J. Tokich as an independent director, announced plans for early share repurchases, and will implement board leadership changes, including Andrew A. Krakauer becoming chairman. The company also intends to form a Growth and Operating Committee to enhance operational execution and identify expansion opportunities. These actions are part of Teleflex's strategy to address its undervalued stock price and continue its divestiture transactions.

Google's 2026 Discover Core Update prioritizes mobile-first delivery of financial content, making insights into Stifel Financial Corp (US8606301021) more accessible to investors. This change means tailored information on Stifel's institutional brokerage, wealth management, and investment banking activities will appear automatically in mobile feeds, leveraging users' past financial interests. The article explains how this development positions investors ahead by providing proactive, high-signal intelligence on Stifel's diversified revenue streams, strategic acquisitions, and market performance.

Revolution Medicines Inc. (RVMD) presented updated Phase 1 clinical trial results for zoldonrasib at the AACR conference, showing promising data for the oral therapy targeting RAS(ON) G12D mutation in NSCLC. Despite the positive clinical news and the company's significant market capitalization in the biotech sector, RVMD has a low GF Score of 36, indicating potential weaknesses in profitability and growth, and has seen significant insider selling. Investors are advised to consider these factors, including the high price-to-book ratio suggesting overvaluation, before making investment decisions.

Sidus Space (Nasdaq: SIDU) announced the pricing of a registered direct offering of 13,453,700 Class A shares or pre-funded warrants at $4.35 per share, aiming to raise approximately $58.5 million in gross proceeds. The net proceeds will be used for working capital and general corporate purposes, with the offering expected to close on April 21, 2026. This move aligns with Sidus's historical pattern of using equity markets for funding, which has previously led to volatile stock reactions and dilution for existing shareholders.

Sidus Space, Inc. has announced the pricing of a registered direct offering for approximately $58.5 million. The offering involves 13,453,700 shares of its Class A common stock or pre-funded warrants at $4.35 per share. The company plans to use the net proceeds for working capital and general corporate purposes, with the closing expected on April 21, 2026.

Simulations Plus Inc. (SLP) reported strong fiscal second-quarter results, exceeding market expectations with an EPS of $0.35 and total revenue of $24.3 million, an 8% year-over-year increase. The growth was driven by increased adoption of AI-enabled modeling in drug development, with software sales accounting for 60% of revenue. The company projects full fiscal year 2026 revenue between $79 million and $82 million and adjusted EPS between $0.75 and $0.85, emphasizing its strategy of integrating AI responsibly into pharmaceutical workflows.

Schrodinger Inc. announced a strategic shift to move 75% of its software contracts to hosted cloud models within three years to meet increasing customer demand for cloud-integrated solutions. The company is collaborating with AI developers like Anthropic and partners such as Eli Lilly to enhance its AI-powered drug discovery tools. Despite a slight revenue decline, Schrodinger surpassed analyst expectations in Q4 2025, driven by a significant increase in drug discovery revenue.

Sallie Mae (Nasdaq: SLM) announced it will release its first-quarter 2026 financial results after market close on Thursday, April 23. The company will host a live audio webcast and presentation slides on its investor relations website at 5:30 p.m. ET on the same day. Investors can find the earnings release and webcast details on Sallie Mae's investor relations website.